PY 159
Alternative Names: PY-159Latest Information Update: 24 Jan 2025
At a glance
- Originator Centre for the Commercialization of Antibodies and Biologics
- Developer Pionyr Immunotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Triggering receptor expressed on myeloid cells-1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 Jan 2025 Ikena Oncology completes a phase I trial in Solid-tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion) before January 2025 (NCT04682431)
- 08 Jan 2025 Foundery Immune Studio acquires PY 314 from Ikena Oncology
- 13 May 2024 PY 159 is available for licensing as of 13 May 2024 (Form 10K, December 2023)